

**AUROBINDO PHARMA LIMITED**  
 Regd. Office: Plot No.2, Mainvihar, Ameerpet, Hyderabad - 500 038, India  
 Unaudited Financial Results for the Quarter ended December 31, 2011

(Rs.in lakhs)

Particulars	Stand alone						Consolidated					
	Three months ended		Nine months ended		Year Ended		Three months ended		Nine months ended		Year Ended	
	31.12.2011 Unaudited	30.09.2011 Unaudited	31.12.2010 Unaudited	31.12.2011 Unaudited	31.12.2010 Unaudited	31.03.2011 Audited	31.12.2011 Unaudited	30.09.2011 Unaudited	31.12.2010 Unaudited	31.12.2011 Unaudited	31.12.2010 Unaudited	Year Ended 31.03.2011 Audited
Sales (including excise duty) & operating income	122,681	97,973	118,421	326,027	314,579	422,999	130,982	109,734	121,980	350,763	330,095	448,098
Less: Excise Duty	2,531	2,204	2,760	7,094	7,124	9,687	2,531	2,204	2,760	7,094	7,387	9,950
Net Sales	120,150	95,769	115,661	318,933	307,455	413,312	128,451	107,530	119,220	343,669	322,708	438,148
Expenditure												
a. (Increase)/Decrease in Stock	5,205	(1,044)	(8,339)	8,497	(9,513)	(13,637)	3,629	355	(10,687)	6,192	(13,876)	(19,016)
b. Material Consumed	62,391	57,763	66,100	175,009	169,650	232,863	55,742	52,245	63,609	160,350	162,238	224,184
c. Purchase of traded goods	1,149	316	372	1,592	664	853	11,177	7,338	4,161	21,276	10,053	13,760
d. Staff Cost	9,377	9,200	7,691	27,294	21,951	30,360	14,076	13,268	10,804	39,661	31,390	42,855
e. Depreciation/Amortisation	3,601	3,436	3,476	10,456	9,360	12,504	5,521	4,622	4,335	14,660	12,413	17,150
f. Other Expenditure	20,470	18,987	16,659	57,418	47,649	67,153	24,711	22,861	19,385	69,218	58,361	80,389
Total Expenditure	102,193	88,658	85,959	280,256	239,761	330,096	114,856	100,689	91,607	311,357	260,579	359,322
Profit from Operations before Other Income, interest, tax & exceptional income	17,957	7,111	29,702	38,677	67,694	83,216	13,595	6,841	27,613	32,312	62,129	78,826
Other Income	168	172	105	513	496	799	494	597	588	1,383	1,957	2,519
Profit before interest, foreign exchange gain, tax and exceptional item	18,125	7,283	29,807	39,190	68,190	84,015	14,089	7,438	28,201	33,695	64,086	81,345
Interest (net)	2,451	1,798	1,020	5,498	3,500	5,049	2,735	2,070	1,146	6,260	4,365	6,247
Foreign Exchange (Gain)/Loss (net)	14,638	14,938	(278)	29,208	(2,127)	(4,450)	14,450	18,542	(408)	32,674	(3,850)	(4,754)
Profit after interest, but before exceptional item and tax	1,036	(9,453)	29,065	4,484	66,817	83,416	(3,096)	(13,174)	27,463	(5,239)	63,571	79,852
Exceptional item	-	-	28,71	2,871	2,871	2,871	-	766	766	31,986	766	1,034
Profit/(Loss) from Ordinary Activities before tax	1,036	(9,453)	26,194	(27,502)	63,946	80,545	(3,096)	(13,174)	26,697	(37,225)	62,805	78,818
Provision for Taxation	(257)	(5,265)	7,809	(14,449)	17,824	21,165	(239)	(5,155)	7,825	(14,070)	18,972	22,512
Profit/(Loss) before Minority Interest	1,293	(4,188)	18,385	(13,053)	46,122	59,380	(2,854)	(8,016)	18,863	(23,150)	43,845	56,306
Minority Interest	1,293	(4,188)	18,385	(13,053)	46,122	59,380	(2,854)	(8,016)	18,863	(23,150)	43,845	56,306
Net Profit/(Loss) for the period	2,911	(2,911)	2,911	2,911	2,911	2,911	2,911	2,911	2,911	2,911	2,911	2,911
Paid-up Equity Share Capital (Face value Re. 1 per share)	0.44	(1.44)	6.31	(4.48)	16.08	20.63	(0.98)	(2.75)	6.48	(7.95)	15.29	241,572
Reserves excluding Revaluation Reserve	0.44	(1.44)	6.31	(4.48)	16.08	20.63	(0.98)	(2.75)	6.48	(7.95)	15.29	19.57
Basic Earnings per share before & after Extraordinary items (Rs.) (not annualised)	0.44	(1.44)	6.31	(4.48)	16.08	20.63	(0.98)	(2.75)	6.48	(7.95)	15.29	19.57
Diluted Earnings per share before & after Extraordinary items (Rs.) (not annualised)	0.44	(1.44)	6.31	(4.48)	16.08	20.63	(0.98)	(2.75)	6.48	(7.95)	15.29	19.57



K. → 11


Public Shareholding																	
- Number of Shares	131,794,307	132,860,775	132,761,795	131,794,307	132,761,795	132,861,495											
- Percentage of Shareholding	45.27	45.64	45.60	45.27	45.60	45.64											
Promoters and promoter group Shareholding																	
a) Pledged/Encumbered																	
- Number of Shares	32,718,605	22,738,605	29,838,605	32,718,605	29,838,605	30,388,605											
- Percentage of Shares (as a % of the total Shareholding of promoter & promoter group)	20.54	14.37	18.84	20.54	18.84	19.20											
- Percentage of Shares (as a % of the total share capital of the company)	11.24	7.81	10.25	11.24	10.25	10.44											
b) Non-encumbered																	
- Number of Shares	126,608,378	135,521,910	128,520,890	126,608,378	128,520,890	127,871,190											
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	79.46	85.63	81.16	79.46	81.16	80.80											
- Percentage of Shares (as a % of the total share capital of the company)	43.49	46.55	44.15	43.49	44.15	43.92											

**NOTES:**

- The above unaudited financial results were reviewed by the Audit Committee and have been approved by the Board at its meeting held on February 13, 2012. A Limited Review of the above stand alone financial results has been carried out by the Statutory Auditors.
- The Consolidated financial results, which are optional, have been presented by the Company, so as to provide additional information.
- The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement' and AS-27 'Financial Reporting of Interests in Joint Ventures' and includes financial results of all Subsidiaries and Joint Ventures.
- The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- Investor complaints pending at the beginning of the quarter: Nil, received: 89, resolved: 89 and lying unresolved at the end of the quarter Nil.
- Sales for the quarter include exports of Rs.88,511 lakhs (Quarter ended Dec-31,2010 : Rs.74,130 lakhs).
- Sales for the quarter include income in standalone of Rs.2,064 lakhs(Quarter ended Dec-31,2010 : Rs.12,651 lakhs) and in consolidated of Rs.2,276 lakhs (Quarter ended Dec-31,2010 : Rs. 12,036 lakhs).
- The outstanding Tranche A and Tranche B Zero Coupon Foreign Currency Convertible Bonds ('FCCB' or 'Bonds') of USD 139.20 Million, issued in May 2006, were repaid in entirety on maturity on May 17, 2011 along with the redemption premium (Yield to Maturity) amounting to Rs. 319.86 crores, inclusive of withholding taxes. The said redemption premium (Yield to Maturity) has been charged to profit and loss account and is disclosed as an exceptional item in the financial results for the nine months. As on date all outstanding FCCBs have been redeemed and extinguished. Previous period exceptional item relates to loss on sale of subsidiaries and joint ventures.
- The Equity Shares of the Company with face value of Rs. 5 per share were sub divided into 5 equity shares of Re.1 each effective February 11, 2011. Consequently, the Basic and Diluted Earning Per Share and shareholding data of the Previous periods have been re-computed and disclosed accordingly.
- During the quarter, the Company has incorporated a wholly owned subsidiary viz. Auro Peptides Limited, India.
- Figures for the previous period/year have been rearranged/ regrouped wherever necessary.

Place: Hyderabad  
Date: February 13, 2012

www.aurobindo.com



By Order of the Board  
K.Nithyananda Reddy  
Managing Director

**Limited Review Report****Review Report to  
The Board of Directors  
Aurobindo Pharma Limited**

1. We have reviewed the accompanying statement of unaudited unconsolidated financial results of Aurobindo Pharma Limited ('the Company') for the quarter ended December 31, 2011 (the "Statement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited unconsolidated financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting", [notified pursuant to the Companies (Accounting Standards) Rules, 2006, (as amended)] and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

S R. Batliboi & Associates  
For S.R. BATLIBOI & ASSOCIATES  
Firm registration number: 101049W  
Chartered Accountants

  
per **Vikas Kumar Pansari**  
Partner  
Membership No.: 93649



Place: Hyderabad  
Date: February 13, 2012